Comparative efficacy of on-demand Sildenafil, Tadalafil and daily Tadalafil for treatment of erectile dysfunction: A 12-week randomized controlled study [PDF]
Indian Journal of PsychiatryBackground: Comparison of available first line agents for treating Erectile Dysfunction (ED) with each other regarding efficacy in Indian context remains scant.
Shevya Gagal +3 more
doaj +2 more sources
Modulating phosphodiesterase-5 activity to suppress the immunosuppressive mechanisms of myeloid-derived suppressor cells in breast cancer [PDF]
Breast Cancer ResearchPhosphodiesterase-5 (PDE5) inhibitors have been shown to have potential as an adjuvant therapy for cancer. Tadalafil is a potent and selective PDE5 inhibitor that has been shown to inhibit the aggregation of myeloid-derived suppressor cells (MDSC) within
Yingxue Guo +12 more
doaj +2 more sources
A Systematic Literature Review Exploring the Efficacy and Safety of Tadalafil and Sildenafil in Pulmonary Arterial Hypertension [PDF]
Pulmonary CirculationPulmonary Arterial Hypertension (PAH) is a rare, chronic and progressive disease affecting the heart and lungs. Endothelin receptor antagonist (ERA) + phosphodiesterase type 5 inhibitor (PDE5i) treatment is recommended for all PAH patients.
Rajan Saggar +9 more
doaj +2 more sources
Potential of tadalafil and tadalafil-cellulose nanocomposite in preventing postsurgical abdominal adhesions in a rat cecal abrasion model [PDF]
Scientific ReportsThe formation of postoperative intra-abdominal adhesions is a significant challenge in veterinary practice worldwide. Thus, several attempts have been made to identify agents that prevent the occurrence of these postsurgical adhesions.
Ahmed Abdelrahiem Sadek +4 more
doaj +2 more sources
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension [PDF]
New England Journal of Medicine, 2015 BACKGROUND: Data on the effect of initial combination therapy with ambrisentan and tadalafil on long-term outcomes in patients with pulmonary arterial hypertension are scarce.
Nazzareno Galie +2 more
exaly +6 more sources
Journal of Pharmacological Sciences, 2022 Podocyte injury is responsible for nephrotic syndrome. Previously, we found that tadalafil, a phosphodiesterase 5 inhibitor, might have protective effects on podocytes.
Natsumi Tomita +7 more
doaj +1 more source
BMJ Open Diabetes Research & Care, 2020 Introduction Sexual dysfunction is a common complication in men with type 2 diabetes and is often refractory to treatment. This study investigated the long-term influence of the phosphodiesterase 5 inhibitor (PDE5I) tadalafil on the level of sex hormones
Akiko Itoga +5 more
doaj +1 more source
Phosphodiesterase Type 5 Inhibitors, Sport and Doping [PDF]
, 2017 Phosphodiesterase type 5 inhibitors (PDE5i) (e.g., sildenafil, tadalafil, vardenafil, and avanafil) are drugs commonly used to treat erectile dysfunction, pulmonary arterial hypertension, and benign prostatic hyperplasia.
Borrione, Paolo +8 more
core +1 more source
Effect of Ticagrelor, a Cytochrome P450 3A4 Inhibitor, on the Pharmacokinetics of Tadalafil in Rats
Pharmaceutics, 2019 Tadalafil is a cytochrome P450 (CYP) 3A4 substrate. Because there are few data on drug-drug interactions, it is advisable to take sufficient consideration when co-administering tadalafil with CYP3A4 inducers or inhibitors.
Young-Guk Na +6 more
doaj +1 more source
Physiological Reports, 2021 Preclinical diastolic dysfunction (PDD) results in impaired cardiorenal response to volume load (VL) which may contribute to the progression to clinical heart failure with preserved ejection fraction (HFpEF).
Siu‐Hin Wan +5 more
doaj +1 more source